Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CD30 inhibitor
DRUG CLASS:
CD30 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
AFM13 (3)
AFM13/AB-101 (1)
CD30 biAb-AATC (0)
GEN3017 (0)
AFM13 (3)
AFM13/AB-101 (1)
CD30 biAb-AATC (0)
GEN3017 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
AFM13/AB-101
Sensitive: B - Late Trials
AFM13 / AB-101
Sensitive
:
B
AFM13/AB-101
Sensitive: B - Late Trials
AFM13 / AB-101
Sensitive
:
B
TNFRSF8 positive
Lymphoma
TNFRSF8 positive
Lymphoma
AFM13
Sensitive: C2 – Inclusion Criteria
AFM13
Sensitive
:
C2
AFM13
Sensitive: C2 – Inclusion Criteria
AFM13
Sensitive
:
C2
TNFRSF8 positive
Hodgkin Lymphoma
TNFRSF8 positive
Hodgkin Lymphoma
AFM13
Sensitive: C2 – Inclusion Criteria
AFM13
Sensitive
:
C2
AFM13
Sensitive: C2 – Inclusion Criteria
AFM13
Sensitive
:
C2
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
AFM13
Sensitive: C3 – Early Trials
AFM13
Sensitive
:
C3
AFM13
Sensitive: C3 – Early Trials
AFM13
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login